Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 90 | ECE2023 | Next issue

25th European Congress of Endocrinology

Istanbul, Turkey
13 May 2023 - 16 May 2023

Card image cap
ECE 2023 will be held in Istanbul, Turkey from 13-16 May 2023. Istanbul is known for its rich culture, historical sites and dynamic nightlife, and we are excited to come together in this city, and look forward to meeting old friends, making new ones, and sharing science, collaborations and ideas.

Oral Communications

Oral Communications 6: Endocrine-related Cancer

ea0090oc6.1 | Oral Communications 6: Endocrine-related Cancer | ECE2023

RNA splicing landscape of pancreatic neuroendocrine neoplasms reveal novel clinico-molecular associations

Blazquez-Encinas Ricardo , Pedraza-Arevalo Sergio , Garcia Vioque Victor , Trinidad Moreno Montilla Maria , Lawlor Rita T , Rovite Vita , Scarpa Aldo , Ibanez Costa Alejandro , P. Castano Justo

Neuroendocrine neoplasms (NENs) are a highly heterogeneous group of tumors that arise from the diffuse neuroendocrine system and whose incidence has increased over the last years. Among them, pancreatic NENs (PanNENs) are relatively common and one of the most studied NENs. PanNENs are characterized by a low number of mutations, with some genes frequently mutated, such as MEN1, ATRX/DAXX, and mTOR signaling pathway genes. Despite genomics, transcripto...

ea0090oc6.2 | Oral Communications 6: Endocrine-related Cancer | ECE2023

Aminoacyl-tRNA synthetases as diagnostic, prognostic, and therapeutic tools in MAFLD-derived hepatocellular carcinoma

Herman-Sanchez Natalia , Lopez-Canovas Juan L. , Amado Victor , Zamora-Olaya Javier M , Rodriguez-Peralvarez Manuel , Luque Raul M , D. Gahete Manuel

Metabolic dysfunction-associated fatty liver disease (MAFLD) is a growing cause of hepatocellular carcinoma (HCCs); however, the molecular characteristics of MAFLD-derived HCCs are still to be elucidated. To provide novel insights in this field, we performed the first quantitative proteomic analysis of HCC samples from different aetiologies. Particularly, cytosolic and nuclear proteome of liver tissues from HCC patients (n=42; HCC vs adjacent tissue) and healthy contr...

ea0090oc6.3 | Oral Communications 6: Endocrine-related Cancer | ECE2023

Tumor microenvironment of adrenocortical carcinoma dissected by single-cell RNA-sequencing

Jouinot Anne , Martin Yoann , Foulonneau Thomas , Bendjelal Yanis , Calvet Philip , Violon Florian , Sibony Mathilde , Daniel De Murat , Armignacco Roberta , Perlemoine Karine , Letourneur Franck , Izac Brigitte , Andrieu Muriel , Berthon Annabel , Ragazzon Bruno , Groussin Lionel , Libe Rossella , Bertherat Jerome , Assie Guillaume

Background: Molecular classification is important for diagnosis and prognosis of adrenocortical tumors (ACT). Transcriptome profiles separate benign ACT (“C2” cluster) from carcinomas (ACC) and identify two groups of ACC, “C1A” (“steroid” and “proliferation” signatures) and “C1B” (“immune” signature), of poor and better prognosis respectively. However, these signatures were characterized at the tissue level (“bul...

ea0090oc6.4 | Oral Communications 6: Endocrine-related Cancer | ECE2023

CAR-T cell therapy exerts effective antitumor efficacy under immunosuppressive conditions in adrenocortical carcinoma

Philipp Schauer Marc , Landwehr Laura-Sophie , Justus Weber , Altieri Barbara , Rodrigo Redundo-Frutos , Tanja Maier , Daniel Oppelt , Kroiss Matthias , Sbiera Silviu , Michael Hudecek , Fassnacht Martin

Background: Adrenocortical carcinoma (ACC) is a very rare and aggressive, endocrine malignancy with still limited treatment options. Approximately 60% of patients with ACC show endogenous glucocorticoid excess which could be one potential cause, why first clinical trials with immunotherapies, like immune checkpoint inhibitors, showed only modest results. Due to the lack of an ACC-specific antigen structure, other immunotherapeutic approaches, like specialized cancer treatments...

ea0090oc6.5 | Oral Communications 6: Endocrine-related Cancer | ECE2023

WEE1 kinase inhibitor, adavosertib (AZD1775), as a novel potential therapeutic strategy in advanced adrenocortical carcinoma

Tamburello Mariangela , Sbiera Silviu , Justus Weber , Lippert Juliane , Detomas Mario , Schauer Marc Philipp , Urlaub Hanna , Steinhauer Sonja , Kimpel Otilia , Landwehr Laura-Sophie , Constanze Hantel , Sigala Sandra , Ronchi Cristina , Hudecek Michael , Katja Kiseljak-Vassiliades , Fassnacht Martin , Altieri Barbara

Background: Adrenocortical cancer (ACC) is a rare malignant neoplasm with a dismal prognosis, particularly in advanced disease. For these patients only limited therapeutic options are available. Adavosertib (AZD1775) is a potent inhibitor of tyrosine kinase WEE1 that regulates cell cycle checkpoints, slowing cell cycle progression and leading to mitotic entry in the presence of DNA damage. Therefore, its use could potentiate existing DNA damage-based therapies. Here, we evalua...

ea0090oc6.6 | Oral Communications 6: Endocrine-related Cancer | ECE2023

Cellular landscape of adrenocortical carcinomas determined by molecular profiling of primary, recurrent and metastatic tumour samples at single-nuclei resolution.

Altieri Barbara , S. Tourigny David , Secener Ali Kerim , Sbiera Silviu , Arampatzi Panagiota , Sauer Sascha , Fassnacht Martin , Ronchi Cristina

Background: Molecular mechanisms of malignant adrenocortical tumorigenesis remain elusive despite previous comprehensive genomic studies. Nonetheless, cellular heterogeneity of primary, recurrent and metastatic adrenocortical carcinoma (ACC) haven’t been fully investigated.Aim: To characterize the molecular profile of different cell subtypes in primary, recurrent and metastatic ACC by single-nuclei RNA sequencing (snRNA-Seq), using adult human norma...